Sight Sciences, Inc.
SGHT Nasdaq· Surgical & Medical Instruments & Apparatus
Last close · Oct 26, 2026
$9.02
KIRA · Stoqly’s AI analyst, in plain words
- Sight Sciences, Inc. had $77.4M of revenue in fiscal 2025, down 3.1% on the year before. Over five years, revenue changed +22.9% a year on average.
- Its operating margin was −48.0%, up 15.3 pts: of every 100 in sales, about −48 is left after running the business.
- Sight Sciences, Inc. lost $38.4M in fiscal 2025.
- Free cash flow was −$29.9M in fiscal 2025, −38.7% of revenue.
- Sight Sciences, Inc. has $49.6M more cash than debt.
Market cap
$492M
P/E
—
Revenue
$77.4M
Net income
−$38.4M
Free cash flow
−$29.9M
Operating margin
−48.0%
Sight Sciences, Inc. in 30 seconds · fiscal 2025
Are sales growing?
−3.1%
No. Sales fell 3.1% last year.
Does it make a profit?
−49.7%
No. It lost money last year.
Does profit turn into cash?
−38.7%
No. It spent more cash than it brought in.
How healthy are the accounts?
5 / 9
Mixed. It passes 5 of 9 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Sight Sciences, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 4, 2026
- Legal name
- Sight Sciences, Inc.
- CIK
- 0001531177
Sight Sciences, Inc. · SGHT
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $49.0M | $71.3M | $81.1M | $79.9M | $77.4M |
| Revenue growth | 77.1% | 45.7% | 13.6% | −1.5% | −3.1% |
| Gross margin | 82.4% | 82.7% | 85.3% | 85.5% | 86.2% |
| Operating margin | −105.2% | −117.7% | −70.7% | −63.3% | −48.0% |
| Net income | −$63.0M | −$86.2M | −$55.5M | −$51.5M | −$38.4M |
| Net margin | −128.6% | −120.9% | −68.5% | −64.5% | −49.7% |
| Diluted EPS | −$2.36 | −$1.80 | −$1.14 | −$1.03 | −$0.74 |
| Cash | |||||
| Cash from operations | −$52.5M | −$76.0M | −$47.2M | −$22.4M | −$29.7M |
| Capital expenditure | $0.8M | $1.0M | $0.8M | $0.4M | $0.2M |
| Free cash flow | −$53.4M | −$76.9M | −$48.0M | −$22.7M | −$29.9M |
| FCF margin | −109.0% | −107.9% | −59.2% | −28.5% | −38.7% |
| Share count change | 185.7% | 79.0% | 1.6% | 3.1% | 4.0% |
| Debt and strength | |||||
| Cash and short-term investments | $261M | $185M | $138M | $120M | $92.0M |
| Debt incl. finance leases | $35.0M | $35.0M | $35.0M | $40.0M | $42.4M |
| Shareholders' equity | $232M | $160M | $120M | $87.5M | $63.9M |
| Current ratio | 20.5x | 11.8x | 13.3x | 9.0x | 10.2x |
| Interest coverage | −11.8x | −18.8x | −10.6x | −10.8x | −7.2x |
| Returns and quality | |||||
| Return on capital | −633.5% | −658.2% | −264.8% | −557.1% | −204.1% |
| Return on equity | −87.9% | −44.0% | −39.6% | −49.6% | −50.7% |
| Return on tangible equity | −27.1% | −53.9% | −46.2% | −58.8% | −60.1% |
| Piotroski F-score | 5 | 3 | 5 | 3 | 5 |
| Altman Z'' | 8.2 | 2.8 | 0.6 | −2.9 | −5.9 |
Insiders bought, 12 months
$0.2M
1 insider
Insiders sold, 12 months
$2.9M
6 insiders
Of sales under plans
76%
$2.2M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Sight Sciences, Inc. · SGHT
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $9.02 a share, the company is worth $492M.
Source: SEC EDGAR XBRL filings (CIK 0001531177). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.